Toripalimab after chemoradiation for older esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests whether adding a drug called toripalimab after standard chemoradiation can help older adults with esophageal cancer. The goal is to see if this treatment can keep the cancer from coming back after initial therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of esophageal cancer called squamous cell carcinoma.
- Your cancer is locally advanced but has not spread to other organs.
- You are between 70 and 85 years old.
- You have not had any cancer treatments before.
- You are healthy enough to be up and caring for yourself (ECOG score 0–2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding the immunotherapy drug toripalimab to standard chemoradiation before surgery helps people with a type of esophageal cancer. It is for patients whose cancer has not spread to other organs and who have not had treatment before.
This trial tests whether adding the immunotherapy drug toripalimab and the chemotherapy pill capecitabine after standard chemoradiotherapy can help prevent esophageal cancer from coming back. It's for people with squamous cell esophageal cancer that hasn't spread far and who have just finished chemoradiotherapy.
This trial studies toripalimab to lower the risk of the cancer coming back after surgery and additional chemo-radiation. It may help the immune system “finish the job” after your main treatment, especially if you have higher-risk features.
This trial tests a new combination of treatments for people with advanced esophageal cancer that can't be removed by surgery. It uses a targeted therapy called surufatinib along with chemo-immunotherapy and radiation to see if it can shrink the tumor before further treatment.
This trial studies whether adding toripalimab (an immunotherapy drug) to standard chemo-radiation before surgery can improve outcomes for people with higher-risk, locally advanced rectal cancer. It is meant for cancers that are mismatch-repair “MSS/pMMR,” and it checks safety plus effectiveness as a first treatment.
This trial is for people with advanced esophageal cancer that hasn't spread far. After initial treatment with chemotherapy, immunotherapy, and radiation, you'll either get toripalimab or just be watched to see which approach works better.
Hear when a new Locally Advanced Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.